Cite
HARVARD Citation
van Kempen, Z. et al. (2023). Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis. Annals of neurology. 93 (1), pp. 103-108. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
van Kempen, Z. et al. (2023). Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis. Annals of neurology. 93 (1), pp. 103-108. [Online].